National Rare Diseases Registry System (NRDRS) – China’s First Nation-Wide Rare Diseases Demographic Analyses

Jian Guo
  Peking Union Medical College Hospital

Peng Liu
  Peking Union Medical College Hospital

Limeng Chen
  Peking Union Medical College Hospital

Haohan Lv
  The Administrative Group of National Rare Diseases Registry System of China

Jie Li
  The Administrative Group of National Rare Diseases Registry System of China

Weichao Yu
  The Administrative Group of National Rare Diseases Registry System of China

Kaifeng Xu
  Peking Union Medical College Hospital

Yicheng Zhu
  Peking Union Medical College Hospital

Zhihong Wu
  Peking Union Medical College Hospital

Zhuang Tian
  Peking Union Medical College Hospital

Ye Jin
  Peking Union Medical College Hospital

Rachel Yang
  The Administrative Group of National Rare Diseases Registry System of China

Weihong Gu
  The Administrative Group of National Rare Diseases Registry System of China

Shuyang Zhang (✉️ zhangsy@nrdrs.org)
  Peking Union Medical College Hospital  https://orcid.org/0000-0003-3160-0845

Research

Page 1/13
Keywords: China, Rare diseases, Registry, Database

DOI: https://doi.org/10.21203/rs.3.rs-597899/v1

License: ☇️ Ⓟ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

China has made remarkable broad and system wide progress in serving the needs of its people living with rare diseases, especially over the last 5 years. The Chinese government’s systematic approach included a series of coordinated initiatives, amongst these are: forming the Rare Disease Expert Committee (2016), to funding the “Rare Diseases Cohort Study” (2016–2020), and to publishing its first “Rare Disease Catalog” (2018). Herein, we present the National Rare Diseases Registry System (NRDRS), China’s first national rare diseases registry, and analysis of the cases registered in the first 5 years ending Dec 31, 2020. The total 62,590 cases covered 166 diseases/disease types, forming 183 disease cohorts. The data from nearly 22% of them (13,947 cases) is also linked to valuable biological samples. The average age of definitive diagnosis was 30.88 years; 36.07% under 18 years of age. Regional distribution analysis showed 60% of cases were from the more developed East and North China, suggesting the local availability of quality care and patients’ financial status were key access factors. Finally, 82.04% of cases were registered from the five clinical departments: Neurology, Endocrine, Hematology, Cardiovascular, and Nephrology, suggesting that either these are most affected by rare diseases, or that there were disease non-specific ascertainment factors. The preliminary analysis of the first 5-year’s data provides unique and valuable insight on rare disease distribution in China, and highlights directions for enhancing equity, scale and utility.

Introduction

The lack of common definition of rare disease makes it challenging to calculate the total number and types of rare diseases in the world. It’s frequently cited there are over 7,000 rare diseases in total [1], although recently Haendel et al gave an estimate of over 10,000 [2]. Rare disease definition is not just a scientific matter, it’s also heavily influenced by the social economic status of a country such that high income countries, such as US, Europe and Japan, include diseases with much higher (0.04%-0.06%) prevalence than low and middle income countries [3]. China doesn’t yet have a nationally endorsed rare disease definition [4]. Using Orphanet’s evidence-based estimated population prevalence of rare diseases of 3.5%-5.9% [5], we calculated China, with its population of 1.4 billion, approximately 49–82 million Chinese are suffering from a rare disease. By the most conservative estimate, China has at least 20 million rare disease patients. Irrespective of the exact number, the social burden of rare diseases in China is huge [6]. Despite the staggering numbers of Chinese affected and the cumulative burden, rare diseases research has historically been limited to tertiary hospitals and single disease or disease type [7]. Knowledge sharing and collaborations among clinicians and hospitals were challenged and limited and there was a severe shortage of nationally coordinated research [8].

Rare diseases have gained increasing recognition as a public health priority in China [7, 9, 10]. Starting 2016, the Chinese government began to further tackle rare diseases with a more well- systematic, cohesive and integrated cross-sector approach. Initially, the Government formed the nation’s First Rare Diseases Expert Committee in Jan 2016 [11]. The multi-disciplinary committee served as a consultation and advisory committee to assist government on rare disease-related policy-making, funding, and other
initiatives. In May 2018, China’s first “Rare Diseases Catalog” was joined published by National Health Commission, Ministry of Science and Technology, Ministry of Industry and Information Technology, National Medical Products Administration, and National Administration of Traditional Chinese Medicine [12]. This was a major milestone for rare disease development in China. The first catalog listed 121 rare diseases and rare disease types. The Second Rare Diseases Expert Committee was formed in September 2020 [13], and has been working on including more rare diseases into the catalog.

In 2016, Peking Union Medical College Hospital (PUMCH) was selected as the lead institution to build the first national rare disease registry (National Rare Diseases Registry System of China; NRDRS), as part of the “Rare Diseases Cohort Study” funded under the nation’s “13th Five-Year Plan” (2016–2020), in the “National Key R&D Program of China – Precision Medicine Initiative” [14]. Table 1 listed the twenty hospitals and universities funded under the “Rare Diseases Cohort Study” and the 5 sub-areas of the study.
### Table 1
“Rare Disease Cohort Study” Research Project and Participating Institutions

| Project Areas                                           | Participating Hospitals                                                                 |
|---------------------------------------------------------|----------------------------------------------------------------------------------------|
| National Rare Diseases Registry System of China (NRDRS) | 1. Chinese Academy of Medical Sciences, Peking Union Medical College Hospital          |
|                                                         | 2. Shanghai Changzheng Hospital                                                          |
|                                                         | 3. Chinese PLA General Hospital                                                          |
|                                                         | 4. The First Affiliated Hospital of Guangzhou Medical University                        |
| Rare Cardiac, Respiratory and Kidney Diseases           | 1. Chinese Academy of Medical Sciences, Beijing Fuwai Hospital*                         |
|                                                         | 2. Shanghai Changzheng Hospital                                                          |
|                                                         | 3. Chinese PLA General Hospital                                                          |
|                                                         | 4. The First Affiliated Hospital of Guangzhou Medical University                        |
| Rare Endocrine Metabolic and Hematological Diseases    | 1. Ruijin Hospital, Shanghai Jiaotong University, School of Medicine*                    |
|                                                         | 2. The First Affiliated Hospital, Zhejiang University, School of Medicine               |
|                                                         | 3. Chinese Academy of Medical Sciences, Institute of Hematology and Blood Diseases Hospital |
|                                                         | 4. Shandong Provincial Hospital                                                          |
|                                                         | 5. Shandong Academy of Medical Sciences                                                  |
| Rare Neurological, Skeletal and Cutaneous Diseases      | 1. West China Hospital, Sichuan University*                                             |
|                                                         | 2. Fudan University                                                                      |
|                                                         | 3. Xiangya Hospital, Central South University                                            |
|                                                         | 4. The First Hospital of China Medical University                                       |
|                                                         | 5. Wenzhou Medical University                                                           |
| Rare Pediatric Diseases                                 | 1. Peking University First Hospital*                                                     |
|                                                         | 2. Capital Institute of Pediatrics                                                      |
|                                                         | 3. Xinhua Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine     |
|                                                         | 4. Beijing Children's Hospital, Capital Medical University                              |
|                                                         | 5. China-Japan Friendship Hospital                                                      |

*The lead institution in each project area

The National Rare Diseases Registry System of China, built as a critical part of the nation’s rare disease infrastructure, was an online rare diseases registry. The goal was to establish national rare disease
registration standards, and to collect standardized rare disease data on cases nation-wide. The NRDRS also served to unify nation's top rare disease centers of excellence to form a national collaborative network [14]. Herein, we present the methods employed for case registration, and results of the analysis of demographic data for the first 5 years, ending 31 Dec, 2020.

**Methods**

**Principal Investigators (PIs) & Participating Hospitals:**

By December 2020, 231 registered users from nation's 85 tertiary hospitals participated in the study. Among them, 81 were Principal Investigators, who were authorized to design new disease forms and start a new cohort for a specific disease/disease type. The remaining users (researchers and research assistants) were limited to using existing disease forms designed by PIs, and enter cases to the PIs’ existing cohorts. All researchers access was limited to only their own cases.

**Case Selection And Data Entry**

The National Rare Diseases Registry System only accepted cases that have a definitive diagnoses by Principal Investigators (PIs) and researchers. Case data were collected by the PIs or researchers and registered in NRDRS by PIs, researchers or their research assistants (RAs).

Two types of forms were created for case registration: the General Form and the Individual Disease Form. The General Form contained patient demographic, social-economic information, diagnostic evidence, biospecimen, genetic test results, and survival status. Information on the General Form must be completed before a researcher could move on to the next stage: entering data on the Individual Disease Forms. Data on Individual Diseases Forms were grouped into 8 categories: Basic information; Disease History; Physical Examination; Ancillary Examination; Therapeutic Intervention; Assessment Scale; Mixed (data belong to more than one category); and Other (data don't belong to any category). There were 183 different Disease Forms in the system, which covered 166 single disease/disease type (17 diseases were represented by two Disease Forms), each designed by a lead expert for a particular disease and used by other researchers in the same cohort. This allowed disease-specific data elements to be captured in NRDRS while maintaining data standards across different researchers and hospitals. The system allowed researchers to complete a case report in multiple steps. Only when all the required information was entered, did the status of the case record become “Completed”. Only completed cases were included in the study.

**Results**

As of December 2020, a total of 62,590 rare disease cases were registered in NRDRS, the majority of the cases were retrospectively ascertained by individual clinicians prior to the intiation of the NRDRS project. As a result, not all desired information was available for all patients. It should also be noted that due to
various reasons, the only age information available to analyze was patient's age at time of visiting the PI or researchers when a definitive diagnosis was made.

Our demographic analysis is shown in Table 2. The average age of obtaining a definitive diagnosis was 30.88 years; 36.07% under 18 years of age, 15.22% in age group 19–30, 13.93% in 31–40, 13.84% in 41–50, and 10.77% in 51–60, 7.23% in 61–70 and 2.94% in ages greater than 71 years of age. More male (55.92%) than female (44.08%) cases were registered in NRDRS.

| Categories  | Number | Percentage (%) |
|-------------|--------|----------------|
| Gender      |        |                |
| Male        | 34,857 | 55.92%         |
| Female      | 27,475 | 44.08%         |
| Age (years) |        |                |
| 0–18        | 18,311 | 36.07%         |
| 19–30       | 7,725  | 15.22%         |
| 31–40       | 7,070  | 13.93%         |
| 41–50       | 7,026  | 13.84%         |
| 51–60       | 5,466  | 10.77%         |
| 61–70       | 3,672  | 7.23%          |
| ≥ 71        | 1,492  | 2.94%          |

To assess the regional distribution of cases (Fig. 1), we used patient's permanent residence instead of the temporary address, because a substantial proportion of China's population is itinerant. China is divided into 7 regions: North China, Northeast China, East China, South China, Central China, Southwest China, and Northwest China. Each region includes several Chinese provinces, which are in close proximity and share certain geographical and cultural features. 60.91% of cases came from higher socioeconomic regions; East and North China. These two regions have the most abundant healthcare resources in China. People in these coastal provinces tend to be more informed, wealthier, and more likely to seek diagnosis and care. The high concentration of PIs and researchers in these two regions could also be a contributing factor.

As rare diseases often affect more than one body system, we wanted to look at case distribution within and across clinical specialty departments (Fig. 2). Rare diseases often impact multiple systems or organs, with compounding symptoms. Patients often went through multiple departments or even hospitals before achieving a definitive diagnosis. All cases in NRDRS were registered by the PIs and researchers who made the final diagnoses. The clinical department of PIs and researchers serves one indicator of the systems most affected by rare diseases.
Our analysis showed that 82.04% of the cases were registered from the following 5 clinical departments: Neurology, Endocrine, Hematology, Cardiovascular, and Nephrology (Fig. 3). We did not include the cases registered from the Pediatric Department in the General Hospitals, nor those from the Children's hospitals, because cases registered from either places provided insufficient information on systems most impacted by the disease.

**Discussions**

China is accelerating its advances to rare diseases, through supporting coordinated researches with increased depth, breadth, inclusivity and equity. It is addressing historical limitation that has typically focused on single disease/disease type, or within specific hospitals, and not enough attention was on setting data standards and quality. The National Rare Diseases Registry System is China's first national rare disease registry that traverses multiple diseases and disease types. As of the end of 2020, the 62,590 registered cases covered 166 single rare disease /disease type, formed a total of 183 cohorts (17 diseases were represented by two cohorts). Furthermore, 13,947 cases contained valuable biological samples.

Approximately one third (61/183) of cohorts had currently more than 200 ascertained cases, contributing more than 92.11% of the total cases. Collectively they covered 52 rare diseases/disease types. Notably, 37 out of the 52 were already on the first “Rare Diseases Catalog”. While it's premature to assess the prevalence of these diseases, the cases in NRDRS provide one indicator of the relative frequency of the diseases, and consistent with experts’ empirical observations. As the “Rare Diseases Expert Committee” continues its work to include more diseases/disease types in the catalog, we hope NRDRS would become an important source of information on rare diseases in China that will enable experts and policy makers to make insight-driven decisions. Acknowledging and addressing potential biases will be critical for making the most informed decisions.

The first 62,590 cases registered in the initial phase of the project (2016–2020) came largely from the PIs of the initial 20 hospitals (Table 1). These were predominantly existing cases accumulated by the PIs from their clinical practices spanning many years, and some inevitably with missing data. Most of the cases came from many other parts of China, after long and odious journeys, got diagnosed and returned to their homes without valid contact information. Follow-up was extremely challenging. Missing critical data elements on existing cases proved one of the big challenges in the initial phase of the project. As we continued to upgrade NRDRS through a combination of better process control for case registration and improved case report form design, we already saw steady improvements on overall case quality. Furthermore, as more existing PIs exhausted their personal case collections, they would start to register more new cases with more data elements. Cases without required data points would not be accepted by the system. We anticipate this prospective ascertainment to increase case quality. The value of NRDRS lies largely with the data it collects, and the insight gained from analyzing the data.
While more than 50% of the rare diseases affect children [15, 16]. Our analysis showed only 36.07% of the cases in NRDRS were under 18 at time of definitive diagnosis. Several factors contributed to the under representation of the pediatric cases. First, NRDRS currently only registered living cases; those who died prior to registration were excluded. Child-onset rare diseases have high mortality, and 30% of the patients don't live to 15 years old [16]. Second, it takes average 6 years for a patient to obtain a final diagnosis [17] and as age was coded at the time of definitive diagnosis, paediatric onset cases may be reflected as “adult cases” in NRDRS. The geographic imbalance of medical resources within China, may further compound the effect of this for rural and remote patients. Finally, under-representation of children's hospitals might have also contributed to the age shift to the right. Among the initial 20 hospitals who received the project funding, only 2 were children’s hospitals. While some of the participating general hospitals also have pediatric departments, children’s hospitals are far more concentrated with pediatric cases. It should be noted that in China only children age 14 and under are considered pediatric. Only 14.05% of total cases were registered from Children's hospitals or Pediatric Departments in General Hospitals. Wakap et al analyzed the Orphanet database and found 69.9% of the rare diseases are exclusively pediatric onset [5]. Rare disease research in children is of particular importance as genomic medicines become more established, and early diagnosis & intervention often lead to marked improvement on outcome and later, quality of life [15, 18]. Recruiting more investigators from nation's children's hospitals, better methods that enhance data asertainment from rural and remote regions will help register more pediatric cases and enhance the value of NRDRS in the future.

This initial collection of cases in NRDRS were mostly historical (retrospective) data from clinician's own case collections, some dated years back, and with their own case report design. Most patients were lost to follow up. Significant number of cases were missing data points, such as age, sex, disease onset, and survival status etc. As NRDRS moved to register more new (prospective) cases, and with better case report form design, we expect to see improvement on case quality. Recruitment open to more hospitals and investigators, especially those from children's hospitals, would expand disease coverage of NRDRS, and provide a more comprehensive view on China's rare disease distribution and population, and pave the way for researches on natural disease history and disease burdens. Insights gained from NRDRS will provide researchers, policy-makers much needed evidence for more informed decision making about interventions to improve the lives of Chinese people and families living with rare diseases.

**Abbreviations**

NRDRS
National Rare Diseases Registry System of China; PUMCH:Peking Union Medical College Hospital;
PIs:Principal Investigators; RAs:Research Assistants

**Declarations**

Ethics approval and consent to participate
The study was reviewed and approved by the Medical Ethics Committee of Chinese Academy of Medical Sciences, Peking Union Medical College Hospital (approval no. JS-1233).

Consent for publication

Not applicable

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the Administrative Group of National Rare Diseases Registry System of China (NRDRS) on reasonable request.

Competing interests

The authors declare that they have no competing interests

Funding

This work was supported by the National Key R&D Program of China (No. 2016YFC0901500).

Authors’ contributions

JG, RY and WG analyzed the data and interpreted the results. PL was responsible for project management. LC, HL, Jl, WY, KX, YZ, ZW, ZT and YJ contributed to data capture and curation. RY and GJ wrote the manuscript. SZ, WG and RY conceived the study design and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Our most sincere appreciation goes to rare disease patients in China. We thank the whole team of the Administrative Group of National Rare Diseases Registry System of China (NRDRS) who contributed to the research work presented in this paper. We’d also like to thank Prof. Gareth Baynam for reviewing the manuscript and providing valuable input.

References

1. Orphanet. 2016 Activity report, orphanet report series, reports collection, July 2017 (V1.1). 2017. http://www.orpha.net/orphacom/cahiers/docs/GB/ActivityReport2016.pdf.
2. Haendel M, Vasilevsky N, Unni D, Bologa C, Harris N, Rehm H, et al. How many rare diseases are there? NAT REV DRUG DISCOV. 2020;19: 77-8.
3. Ferreira CR. The burden of rare diseases. Am J Med Genet A. 2019;179: 885-92.
4. Yazhou Cui, Jinxiang Han. Defining rare diseases in China. Intractable Rare Dis Res. 2017;6(2): 148-9.
5. Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. European journal of human genetics. 2020;28: 165-73.

6. Dong Dong, You Wang. Challenges of rare diseases in China. Lancet. 2016;387: 1906.

7. Li Yang, Chang Su, Ashley M. Lee, Harrison X. Bai. Focusing on rare diseases in China: are we there yet? Orphanet J Rare Dis. 2015;10: 142.

8. ShuyYang Zhang, Limeng Chen, Zongjiu Zhang, Yupei Zhao. Orphan drug development in China: progress and challenges. Lancet. 2019;394: 1127-8.

9. Yazhou Cui, Xiaoyan Zhou, Han J. China launched a pilot project to improve its rare disease healthcare levels. Orphanet J Rare Dis. 2014;9: 1-3.

10. Chen K, Yao L, Liu Z. Towards government-funded special biomedical research programs to combat rare diseases in China. Biosci Trends. 2015;9: 88-90.

11. National Health Commission of the People's Republic of China. Notice of the General Office of National Health and Family Planning Commission of the People's Republic of China on the Establishment of the Expert Committee on Diagnosis, Treatment and Protection of Rare Diseases of the National Health and Family Planning Commission [online, in Chinese]. 2015. http://www.nhc.gov.cn/zyygj/s7659/201601/c918591a06154c1ea193fc32ba93c085.shtml.

12. National Health Commission of the People's Republic of China. Notice on the publication of the first list of rare diseases [online, in Chinese]. 2018. http://www.nhc.gov.cn/zyygj/s7659/201806/393a9a37f39c4b458d6e830f40a4bb99.shtml.

13. National Health Commission of the People's Republic of China. Notice of the General Office of National Health Commission on Publishing the List of the Second Expert Committee on Diagnosis, Treatment and Protection of Rare Diseases of the National Health Commission [online, in Chinese]. 2020. http://www.nhc.gov.cn/zyygj/s7659/202009/c4cf28e6b54a4d248f0611b50dc023e7.shtml.

14. Jian Guo, Haohan Lv, Jie Li, Weichao Yu, Peng Liu, Weihong Gu, Shuyang Zhang. National Rare Diseases Registry System of China: Optimizing System Architecture and Enhancing Data Quality [in Chinese]. China Digital Medicine. 2021;16(1): 17-22.

15. Wright CF, FitzPatrick DR, Firth HV. Paediatric genomics: diagnosing rare disease in children. Nat Rev Genet. 2018;19: 253-68.

16. Bick D, Jones M, Taylor SL, Taft RJ, Belmont J. Case for genome sequencing in infants and children with rare, undiagnosed or genetic diseases. J Med Genet. 2019;56: 783-91.

17. Bloss S, Klemann C, Rother AK, Mehmecke S, Schumacher U, Mucke U, et al. Diagnostic needs for rare diseases and shared prediagnostic phenomena: Results of a German-wide expert Delphi survey. PloS one. 2017;12: e0172532.

18. Zurynski Y, Gonzalez A, Deverell M, Phu A, Leonard H, Christodoulou J, et al. Rare disease: a national survey of paediatricians' experiences and needs. BMJ Paediatr Open. 2017;1: e000172.
Figure 1

Please see the Manuscript file for the complete figure caption. Note: The designations employed and the presentation of the material on this map do not imply the expression of any opinion whatsoever on the part of Research Square concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. This map has been provided by the authors.
Figure 2

Distribution of rare disease cases across different clinical departments * The patients registered from department of pediatrics (8,793) were not included in this figure.